Featured Research

from universities, journals, and other organizations

Genetic aberration paves the way for new treatment of cancer disease

Date:
November 6, 2013
Source:
University of Copenhagen
Summary:
Researchers have characterized a genetic aberration on a group of colorectal cancer patients. The discovery gives hope for a new and efficient treatment of colorectal cancer, which is a frequent and often fatal disease.

Researchers from Faculty of Health and Medical Sciences, University of Copenhagen, have characterized a genetic aberration on a group of colorectal cancer patients. The discovery gives hope for a new and efficient treatment of colorectal cancer, which is a frequent and often fatal disease. The research was recently published in Scandinavian Journal of Gastroenterology.

12-15 years of development and millions of dollars are typically the costs, when companies develop a new anti-cancer drug. Therefore all short cuts to a treatment are welcome. Researchers at Department of Veterinary Disease Biology, University of Copenhagen, recently discovered such a potential short cut.

"Our new research shows, that we might be able to introduce a treatment faster and cheaper than usual in the development of cancer treatment, and we estimate that it will be efficient in around 10 per cent of patients with colorectal cancer," says MD and PhD student Sune Nygård, Department of Veterinary Disease Biology, University of Copenhagen.

Re-use of existing breast cancer treatment

In the new study the researchers have shown that around 10 per cent of colorectal cancer patients harbor an aberration in the gene called TOP2A in their cancer cells. These tumors could potentially benefit from treatment with a specific chemotherapeutic drug -- a so-called "anti-TOP2A treatment," which is already used in breast cancer patients with this gene aberration.

Clinical study begins

Approximately 600,000 patients die of colorectal cancer each year worldwide.

"If the first treatment doesn't cure a patient with colorectal cancer, the possibilities of additional treatment are limited," says Nils Brünner, MD, professor at University of Copenhagen. "Therefore it is very important to find a new, efficient treatment," he adds.

The research group from the Department of Veterinary Disease Biology and professor Per Pfeiffer at Odense University Hospital have received funds from The Danish Cancer Society to initiate a clinical trial. Here it will be tested, if patients with the TOP2A gene defect could benefit from the targeted anti-TOP2A treatment.

"It is unique to go from a discovery in the laboratory towards a treatment for cancer patients at this pace. This is only possible when researchers and doctors work closely together," says Nils Brünner, University of Copenhagen.


Story Source:

The above story is based on materials provided by University of Copenhagen. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sune Boris Nygård, Ib Jarle Christensen, David Hersi Smith, Signe Lykke Nielsen, Niels Frank Jensen, Hans Jørgen Nielsen, Ben Vainer, Nils Brünner. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer. Scandinavian Journal of Gastroenterology, 2013; 1 DOI: 10.3109/00365521.2013.848230

Cite This Page:

University of Copenhagen. "Genetic aberration paves the way for new treatment of cancer disease." ScienceDaily. ScienceDaily, 6 November 2013. <www.sciencedaily.com/releases/2013/11/131106101624.htm>.
University of Copenhagen. (2013, November 6). Genetic aberration paves the way for new treatment of cancer disease. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/11/131106101624.htm
University of Copenhagen. "Genetic aberration paves the way for new treatment of cancer disease." ScienceDaily. www.sciencedaily.com/releases/2013/11/131106101624.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) — Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) — According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) — The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins